Article Figures & Data
Figures
- Figure 1.
RADAR: ACUITY Bleeding Through 30 Days
REG1=pegnivacogin plus control agent, anivamerson.
Reproduced from Povsic TJ et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 2013;34(31)248–2489. With permission from Oxford University Press.
Tools
Strategies to Optimize Antiplatelet Effects and Minimize Bleeding in NSTE-ACS
Permalink:
